A recent meta-analysis of nine RCTs, including 8920 patients with heart failure and type 2 diabetes, reported a 13% reduction in MACEs with GLP-1 RA treatment compared with placebo [50]; however, this analysis did not differentiate between heart failure phenotypes, highlighting the need for more nuanced investigations specifically focused on HFpEF. This evidence concerns the gene GLP1R and heart failure.